Lyell Immunopharma (NASDAQ:LYEL) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Key Points

• Shares fell below their 200-day moving average of $16.46, trading as low as $15.50 and last quoted at $15.64; the article also reports a 7.2% decline.
• Analyst sentiment remained broadly positive: MarketBeat reported a “Moderate Buy” consensus and an average price target of $40.86, though ratings included one Sell.
• Lyell reported a quarterly loss of $1.86 per share, better than the $2.01 loss analysts expected, with no revenue. A major shareholder also bought 2.32 million shares at an average $10.77 each.

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s share price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $16.46 and traded as low as $15.50. Lyell Immunopharma shares last traded at $15.64, with a volume of 130,954 shares.

Analyst Ratings Changes

A number of equities analysts recently commented on LYEL shares. Citigroup reaffirmed a "market outperform" rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. HC Wainwright reaffirmed a "buy" rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a report on Friday, August 14th. Finally, Wall Street Zen raised Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Sunday, October 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.86.

Lyell Immunopharma Stock Down 7.2%

The stock has a market capitalization of $384.59 million, a PE ratio of -1.25 and a beta of -0.04. The stock's 50 day moving average price is $10.99 and its 200-day moving average price is $16.46.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($2.01) by $0.15. Lyell Immunopharma had a negative net margin of 1,701,066.75% and a negative return on equity of 107.62%. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, sell-side analysts predict that Lyell Immunopharma, Inc. will post -7.16 earnings per share for the current fiscal year.

Insider Transactions at Lyell Immunopharma

In related news, major shareholder Venture Fund Xiii L.P. Arch bought 2,321,262 shares of Lyell Immunopharma stock in a transaction dated Wednesday, November 4th. The shares were acquired at an average cost of $10.77 per share, with a total value of $24,999,991.74. Following the completion of the transaction, the insider owned 3,747,790 shares in the company, valued at $40,363,698.30. The trade was a 162.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Arch Venture Partners Ix, Llc purchased 2,321,262 shares of the firm's stock in a transaction dated Wednesday, November 4th. The shares were bought at an average cost of $10.77 per share, with a total value of $24,999,991.74. Following the purchase, the insider directly owned 3,747,790 shares of the company's stock, valued at approximately $40,363,698.30. This represents a 162.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 2,100 shares of company stock worth $28,757 over the last 90 days. Insiders own 6.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Opaleye Management Inc. increased its holdings in Lyell Immunopharma by 334.9% during the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company's stock worth $4,834,000 after purchasing an additional 264,928 shares during the period. venBio Partners LLC bought a new stake in Lyell Immunopharma during the 2nd quarter valued at $4,744,643. Renaissance Technologies LLC raised its position in Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company's stock valued at $2,335,000 after purchasing an additional 76,921 shares in the last quarter. Velan Capital Investment Management LP lifted its holdings in shares of Lyell Immunopharma by 2.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company's stock worth $1,475,000 after buying an additional 3,000 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in shares of Lyell Immunopharma during the 1st quarter worth $959,000. Institutional investors own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells' ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company's investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient's own immune cells, which are modified or selected and expanded before being administered as a potential treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.